These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20237027)

  • 21. Cingulate gyrus volume and metabolism in the schizophrenia spectrum.
    Haznedar MM; Buchsbaum MS; Hazlett EA; Shihabuddin L; New A; Siever LJ
    Schizophr Res; 2004 Dec; 71(2-3):249-62. PubMed ID: 15474896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurochemical imaging in schizophrenia.
    Urban N; Abi-Dargham A
    Curr Top Behav Neurosci; 2010; 4():215-42. PubMed ID: 21312402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human brain mapping under increasing cognitive complexity using regional cerebral blood flow measurements and positron emission tomography.
    Law I
    Dan Med Bull; 2007 Nov; 54(4):289-305. PubMed ID: 18208679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging dopamine transmission in schizophrenia. A review and meta-analysis.
    Laruelle M
    Q J Nucl Med; 1998 Sep; 42(3):211-21. PubMed ID: 9796369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Structural and functional cerebral changes in patients with schizophrenia].
    Rubin PJ; Hemmingsen RP
    Ugeskr Laeger; 1993 Jan; 155(1):16-21. PubMed ID: 8421841
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Hazlett EA; Vaccaro DH; Haznedar MM; Goldstein KE
    Psychiatry Res; 2019 Jan; 271():535-540. PubMed ID: 30553101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.
    Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K
    Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse.
    Rominger A; Wagner E; Mille E; Böning G; Esmaeilzadeh M; Wängler B; Gildehaus FJ; Nowak S; Bruche A; Tatsch K; Bartenstein P; Cumming P
    Synapse; 2010 Apr; 64(4):313-22. PubMed ID: 19957365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.
    Wong DF; Kuwabara H; Horti AG; Raymont V; Brasic J; Guevara M; Ye W; Dannals RF; Ravert HT; Nandi A; Rahmim A; Ming JE; Grachev I; Roy C; Cascella N
    Neuroimage; 2010 Oct; 52(4):1505-13. PubMed ID: 20406692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular imaging of psychiatric disorders].
    Takahashi H; Suhara T
    Nihon Rinsho; 2007 Feb; 65(2):336-41. PubMed ID: 17302281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET.
    Nozaki S; Kato M; Takano H; Ito H; Takahashi H; Arakawa R; Okumura M; Fujimura Y; Matsumoto R; Ota M; Takano A; Otsuka A; Yasuno F; Okubo Y; Kashima H; Suhara T
    Schizophr Res; 2009 Mar; 108(1-3):78-84. PubMed ID: 19056247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography.
    Potkin SG; Alva G; Fleming K; Anand R; Keator D; Carreon D; Doo M; Jin Y; Wu JC; Fallon JH
    Am J Psychiatry; 2002 Feb; 159(2):227-37. PubMed ID: 11823264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of positron emission tomography in psychiatry.
    Parsey RV; Mann JJ
    Semin Nucl Med; 2003 Apr; 33(2):129-35. PubMed ID: 12756645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.
    Lehrer DS; Christian BT; Kirbas C; Chiang M; Sidhu S; Short H; Wang B; Shi B; Chu KW; Merrill B; Buchsbaum MS
    Schizophr Res; 2010 Sep; 122(1-3):43-52. PubMed ID: 20655709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into schizophrenia using positron emission tomography: building the evidence and refining the focus.
    Vyas NS; Patel NH; Nijran KS; Al-Nahhas A; Puri BK
    Br J Psychiatry; 2010 Jul; 197(1):3-4. PubMed ID: 20592424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PET tracers for imaging of the dopaminergic system.
    Elsinga PH; Hatano K; Ishiwata K
    Curr Med Chem; 2006; 13(18):2139-53. PubMed ID: 16918344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Functional imaging in mental disorders].
    Borbély K
    Orv Hetil; 2004 Feb; 145(6):277-89. PubMed ID: 15038321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of anti-psychotic agents on brain glucose metabolism and regional cerebral circulation in patients with schizophrenia-- study by functional brain imaging of SPECT and PET].
    Jibiki I
    Seishin Shinkeigaku Zasshi; 2002; 104(2):144-51. PubMed ID: 11985069
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.